Eisai to Divest Rights for Pariet in China to Peak Pharma
TOKYO, Apr 1, 2025 – (JCN Newswire) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet® (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company…
Read More
0
